Copley Acquisition opened at $10.80, in line with its previous close of $10.80. In the last trading session, the stock traded between $10.75 and $10.80. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Copley Acquisition is now worth
$ 107.49
Giving a profit of
$ 7.49 (7.49%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.05 (-0.47%)
Day High
$10.80
Day Low
$10.75
Day Open
$10.80
Prev Close
$10.80
Volume
334
1W Return
0.93%
1M Return
1.42%
3M Return
2.42%
6M Return
3.55%
1Y Return
5.38%
Fundamentals
Market Cap ($ Mn)
185
PE Ratio
40.35
PB Ratio
1.42
PEG Ratio
-
ROE
4.03%
ROCE
3.90%
EPS (TTM)
-
Investment Returns
1 Week
0.93%
1 Month
1.42%
3 Months
2.42%
6 Months
3.55%
9 Months
4.61%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
6Nov
Copley Acquisition Corp extends SPAC deadline to November 2027
Shareholders approved extending the business combination deadline to November 2, 2027. Approximately $137.1 million was redeemed from the trust account at $10.63 per share. Sponsor provided a $2.4 million promissory note to fund monthly extension deposits. Trust account balance reduced to approximately $46.2 million following redemptions.
7 days ago
14Oct
Copley Acquisition and Ignite Proteomics end merger deal
Copley Acquisition Corp and Ignite Proteomics mutually terminated their business combination agreement. The termination is effective October 9, 2026. All rights and obligations under the original agreement are ended, except for specific surviving sections.
1mo ago
11Jun
Copley to merge with Ignite Proteomics at $150M pro forma EV
Copley Acquisition Corp and Ignite Proteomics have entered into a definitive business combination agreement to merge at a pro forma enterprise value of $150 million, creating Ignite Proteomics Holdings, Inc. The transaction, expected to close in the second half of 2026, aims to advance precision oncology through pathway-level protein analytics. Leadership from both companies highlighted the strategic fit and the potential to scale commercial infrastructure.
